BillionToOne Outperforms Medical Sector with 49.5% Year-to-Date Return

Industry
โดย Zacks Investment Research·Read original
Summary · why it matters

BillionToOne has returned about 49.5% since the start of the calendar year, significantly outperforming the Medical sector's average return of 1.1%. The company holds a Zacks Rank of 2, or Buy, and its full-year earnings estimate has been revised 122% higher over the past three months. Within the Medical Products industry, which has lost an average of 22% year-to-date, BillionToOne's performance stands out. Another Medical sector stock, Concentra Group, has returned 56.4% year-to-date and also carries a Zacks Rank of 2, with its earnings estimate up 3.9% over three months.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
BillionToOne, Inc. Class A Common Stock
BLLN
▲ PositiveCapitalrelevance

BillionToOne's 49.5% YTD return, Zacks Rank 2 (Buy), and 122% upward earnings revision indicate strong financial performance and positive analyst sentiment.

Health Care▲ · 1 stocks
© 2026 MarketDXNews